These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21171912)

  • 21. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
    Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients.
    Chiu M; Ko DT; Austin PC; Cohen EA; Velianou JL; Goeree R; Blackhouse G; Tu JV
    Circ Cardiovasc Qual Outcomes; 2009 Mar; 2(2):96-107. PubMed ID: 20031821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Left main coronary artery stenting: crossing the Rubicon.
    Alfonso F
    J Am Coll Cardiol; 2009 May; 53(19):1769-72. PubMed ID: 19422983
    [No Abstract]   [Full Text] [Related]  

  • 24. Sirolimus- versus paclitaxel-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials.
    Piccolo R; Cassese S; Galasso G; De Rosa R; D'Anna C; Piscione F
    Int J Cardiol; 2011 Jan; 146(2):234-6. PubMed ID: 21067831
    [No Abstract]   [Full Text] [Related]  

  • 25. Xience V everolimus-eluting coronary stent.
    Kukreja N; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiographic patterns of restenosis with 2nd generation drug-eluting stent: comparative analysis from a 10-year single-center experience .
    Lee S; Yoon CH; Oh IY; Suh JW; Cho YS; Cho GY; Chae IH; Choi DJ; Youn TJ
    Int Heart J; 2015; 56(1):6-12. PubMed ID: 25503656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
    Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
    J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of the Xience V® everolimus-eluting coronary stent system.
    Claessen BE; Caixeta A; Henriques JP; Piek JJ
    Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1363-74. PubMed ID: 20936921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
    Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
    Mahmud E; Bromberg-Marin G; Palakodeti V; Ang L; Creanga D; Demaria AN
    J Am Coll Cardiol; 2008 Jun; 51(25):2385-95. PubMed ID: 18565394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with chronic renal insufficiency.
    Syed AI; Ben-Dor I; Collins SD; Gonzalez MA; Gaglia MA; Torguson R; Satler LF; Suddath WO; Pichard AD; Lindsay J; Waksman R
    J Interv Cardiol; 2010 Feb; 23(1):33-9. PubMed ID: 20465718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials.
    Onuma Y; Serruys PW; Kukreja N; Veldhof S; Doostzadeh J; Cao S; Stone GW;
    Eur Heart J; 2010 May; 31(9):1071-8. PubMed ID: 20118171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
    Stone GW; Rizvi A; Newman W; Mastali K; Wang JC; Caputo R; Doostzadeh J; Cao S; Simonton CA; Sudhir K; Lansky AJ; Cutlip DE; Kereiakes DJ;
    N Engl J Med; 2010 May; 362(18):1663-74. PubMed ID: 20445180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
    Kereiakes DJ; Smits PC; Kedhi E; Parise H; Fahy M; Serruys PW; Stone GW
    EuroIntervention; 2011 May; 7(1):74-83. PubMed ID: 21550906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of outcomes in patients with insulin-dependent versus non-insulin dependent diabetes mellitus receiving drug-eluting stents (from the first phase of the prospective multicenter German DES.DE registry).
    Akin I; Bufe A; Eckardt L; Reinecke H; Senges J; Richardt G; Kuck KH; Schneider S; Nienaber CA;
    Am J Cardiol; 2010 Nov; 106(9):1201-7. PubMed ID: 21029813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of rapamycin as compared to paclitaxel-eluting stents: a meta-analysis.
    Juwana YB; Rasoul S; Ottervanger JP; Suryapranata H
    J Invasive Cardiol; 2010 Jul; 22(7):312-6. PubMed ID: 20603502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.